Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» HAE
HAE
Upcoming events – key tests approach for Biogen and Kalvista
EP Vantage
Fri, 05/24/19 - 10:42 am
Biogen
BIIB098
Tecfidera
multiple sclerosis
KalVista
HAE
Biocryst
BCX7353
KVD900
BioCryst shares are blasted as a PhIII HAE 'success' underwhelms analysts
Endpoints
Tue, 05/21/19 - 09:51 am
Biocryst
HAE
clinical trials
BCX7353
Shire's drug for rare swelling disorder wins European panel green light
Reuters
Sat, 10/20/18 - 11:04 pm
EMA
Europe
Shire
Takhzyro
HAE
BioCryst says oral drug works for HAE attacks
Fierce Biotech
Tue, 09/4/18 - 11:02 am
Biocryst
BCX7353
clinical trials
HAE
hereditary angiodema
Shire Secures FDA Approval for HAE Drug Lanadelumab
BioSpace
Fri, 08/24/18 - 11:23 am
Shire
Takeda
HAE
hereditary angiodema
Takhzyro
lanadelumab
FDA
Adverum Biotechnologies Receives Orphan Drug Designation for Hereditary Angioedema Gene Therapy Candidate
CP Wire
Fri, 08/24/18 - 11:00 am
Adverum Biotechnologies
ADVM-053
hereditary angiodema
HAE
FDA
Shire dodges pricing questions as lanadelumab’s big day nears
EP Vantage
Fri, 08/10/18 - 09:30 am
Takeda
HAE
lanadelumab
FDA
Shire scores new FDA thumbs-up for HAE drug Cinryze in latest bid to fend off rival CSL
Fierce Pharma
Thu, 06/21/18 - 12:02 pm
CSL
HAE
Shire
Cinryze
Haegarda
Shire's HAE candidate boosted by new Phase 3 data
Biopharma Dive
Tue, 03/6/18 - 09:31 am
Shire
HAE
clinical trials
lanadelumab
Shire set for in-house production of rare disease drug Cinryze after shortage issues
Fierce Pharma
Thu, 01/25/18 - 12:00 am
Shire
Cinryze
drug shortages
HAE
drug manufacturing
Shire says trial shows new HAE drug significantly reduces attacks
Reuters
Tue, 09/12/17 - 10:15 am
Shire
HAE
clinical trials
hereditary angiodema
SHP616
FDA OKs CSL’s new HAE drug, already embroiled in a blockbuster fight with Shire
Endpoints
Fri, 06/23/17 - 09:48 am
FDA
CSL
HAE
hereditary angiodema
Shire
Haegarda
Firazyr
Kalbito
Shire Is Poised To Dominate The HAE Market After Strong Phase III Data For SHP643
Seeking Alpha
Mon, 05/22/17 - 07:43 pm
Shire
HAE
SHP643
lanadelumab
Shire’s multibillion-dollar gamble on lanadelumab pays off with stellar PhIII data, quick marketing application
Endpoints
Thu, 05/18/17 - 09:38 am
Shire
lanadelumab
DX-2930
HAE
Cinryze
Dyax
Shire, armed with new rare disease patent, aims to block CSL's Haegarda launch
Fierce Pharma
Mon, 04/17/17 - 04:10 pm
Shire
rare disease
CSL
patents
Haegarda
HAE
hereditary angiodema
How Does Shire Lead the Angioedema Space?
Yahoo/Market Realist
Wed, 04/27/16 - 09:08 am
Shire
Cinryza
Firazyr
HAE
hereditary angiodema
8 Major Biopharma Events Coming Later in 2016 and in 2017
24/7 Wall St
Tue, 03/29/16 - 10:33 pm
Vertex Pharmaceuticals
VX-661
cystic fibrosis
Incyte
ruxolitinib
colorectal cancer
breast cancer
Ultragenyx
KRN23
osteomalacia
GW Pharma
Epidiolex
Puma Biotechnology
neratinib
Celator Pharmaceuticals
Vyxeos
Biocryst
OPuS-2
BCX7353
HAE
Galena Biopharma
NeuVax
trastuzumab
Dyax banks on drug designation news
Bizjournals.com
Tue, 07/7/15 - 12:28 pm
Dyax
DX-2930
HAE
hereditary angiodema
Dyax's Threat to $630,000 Shire Drug Makes It a Target
Bloomberg
Thu, 06/11/15 - 10:13 am
Shire
Dyax
DX-2930
HAE
hereditary angiodema
Cinryze
Pharming and Salix: HAE Trial's First Patient Treated
Drug Discovery and Development
Fri, 01/9/15 - 08:05 am
Pharming Group
Salix
HAE
clinical trials
hereditary angiodema
Ruconest
Pages
« first
‹ previous
1
2
3
next ›
last »